輝瑞疫苗失效？以色列完全接種者感染變異毒株
Sy Mukherjee
2021-07-01
由于此前在完全接種了輝瑞公司（Pfizer）新冠疫苗的成年人中出現了少量新冠病毒變異的陽性病例，以色列衛生部官員將重啟室內口罩令。普遍意義上的完全接種新冠疫苗是指已經接種了兩針疫苗，并且距離第二針接種已經過去了兩周。
德爾塔變異毒株已經迅速成為新冠肺炎病例在印度和英國等某些國家的疫情主要來源。在美國的新病例中也占了越來越多的份額，主要集中在疫苗接種率低的州。這種突變最初在印度發現，似乎比新型冠狀病毒的傳播性強得多，可能對年輕人構成特別威脅。
據《華爾街日報》（Wall Street Journal）報道，以色列政府的疫情研究專家預計，以色列約90%的新病例將與德爾塔變異毒株有關。在專家檢測的感染德爾塔變異毒株的病例中，約有一半發生在16歲以下未接種疫苗的兒童中。但在此次疫情中感染的成年人里，約有一半已經接種了新冠疫苗。
不過現在還不是草木皆兵的時候。早期的研究表明，在德爾塔變異毒株肆虐的英國，輝瑞疫苗在完全免疫的人群中，預防住院患者感染德爾塔變異毒株方面，有效率達到96%。據以色列政府的新冠疫情研究專家蘭?巴利塞說：“在過去五天里，以色列只記錄了5例新冠肺炎重癥病例。當然，病例數、住院人數（以及死亡人數）這些數據都相對滯后。輝瑞疫苗在預防感染新冠肺炎德爾塔變異毒株方面是否有效，或者是否需要注射加強針來預防，這些問題還需要時間來檢驗。”
輝瑞公司對其疫苗對抗德爾塔變異毒株的有效性充滿信心。據路透社（Reuters）報道，輝瑞公司的以色列醫療主任阿隆?拉帕波特對以色列當地電視臺表示：“我們今天積累的數據源于我們在實驗室進行的研究，包括來自印度德爾塔變異毒株取代英國變種成為常見病毒變種的數據，表明我們的疫苗對預防新冠肺炎的有效率約90%。”
簡而言之，至少還需要幾個月的時間才能夠了解現有的新冠疫苗對德爾塔變異毒株起到何種作用。（財富中文網）
編譯：於欣
由于此前在完全接種了輝瑞公司（Pfizer）新冠疫苗的成年人中出現了少量新冠病毒變異的陽性病例，以色列衛生部官員將重啟室內口罩令。普遍意義上的完全接種新冠疫苗是指已經接種了兩針疫苗，并且距離第二針接種已經過去了兩周。
德爾塔變異毒株已經迅速成為新冠肺炎病例在印度和英國等某些國家的疫情主要來源。在美國的新病例中也占了越來越多的份額，主要集中在疫苗接種率低的州。這種突變最初在印度發現，似乎比新型冠狀病毒的傳播性強得多，可能對年輕人構成特別威脅。
據《華爾街日報》（Wall Street Journal）報道，以色列政府的疫情研究專家預計，以色列約90%的新病例將與德爾塔變異毒株有關。在專家檢測的感染德爾塔變異毒株的病例中，約有一半發生在16歲以下未接種疫苗的兒童中。但在此次疫情中感染的成年人里，約有一半已經接種了新冠疫苗。
不過現在還不是草木皆兵的時候。早期的研究表明，在德爾塔變異毒株肆虐的英國，輝瑞疫苗在完全免疫的人群中，預防住院患者感染德爾塔變異毒株方面，有效率達到96%。據以色列政府的新冠疫情研究專家蘭?巴利塞說：“在過去五天里，以色列只記錄了5例新冠肺炎重癥病例。當然，病例數、住院人數（以及死亡人數）這些數據都相對滯后。輝瑞疫苗在預防感染新冠肺炎德爾塔變異毒株方面是否有效，或者是否需要注射加強針來預防，這些問題還需要時間來檢驗。”
輝瑞公司對其疫苗對抗德爾塔變異毒株的有效性充滿信心。據路透社（Reuters）報道，輝瑞公司的以色列醫療主任阿隆?拉帕波特對以色列當地電視臺表示：“我們今天積累的數據源于我們在實驗室進行的研究，包括來自印度德爾塔變異毒株取代英國變種成為常見病毒變種的數據，表明我們的疫苗對預防新冠肺炎的有效率約90%。”
簡而言之，至少還需要幾個月的時間才能夠了解現有的新冠疫苗對德爾塔變異毒株起到何種作用。（財富中文網）
編譯：於欣
Israeli health officials are returning to mask mandates at indoor facilities following a small spate of positive COVID Delta variant cases in adults who had been fully vaccinated with Pfizer's coronavirus vaccine. That is, these adults had received two doses of the vaccine, and it had been two weeks since their second dose, the generally accepted timeline for full vaccination.
The Delta variant has rapidly become the main source of new COVID cases in certain parts of the globe including India and the U.K. It also makes up an increasing share of new cases in the U.S., clustered in states with low vaccination rates. The mutation, originally identified in India, appears to be far more transmissible than the novel coronavirus and could be a particular threat to younger people.
In Israel, expert advisers to the government estimate that about 90% of new cases are linked to the Delta variant, according to the Wall Street Journal. About half of the Delta variant cases examined by experts occurred in children under the age of 16 who haven’t been vaccinated. But about half of adults who were infected in this outbreak were fully immunized with the COVID vaccine.
That doesn’t mean it’s time to panic quite yet. Early studies in the U.K., where the Delta variant is also prominent, have suggested that the Pfizer vaccine in fully immunized people is 96% effective at preventing hospitalizations for those who become infected with the Delta variant. And in the past five days, Israel has recorded only five severe cases of COVID, according to Ran Balicer, a COVID adviser to the Israeli government. Of course, illness and hospitalizations (and deaths) are all lagging indicators. It will take more time to tell just how effective Pfizer's vaccine is at preventing debilitating COVID illness in those with the Delta variant, or whether booster shots will be required to address it.
Pfizer is sounding a confident note in its vaccine's efficacy against the strain. “The data we have today, accumulating from research we are conducting at the lab and including data from those places where the Indian variant, Delta, has replaced the British variant as the common variant, point to our vaccine being very effective, around 90%, in preventing the coronavirus disease, COVID-19,” Pfizer’s Israel medical director Alon Rappaport told a local Israeli station, according to Reuters.
In short：It’s going to take at least a few more months to get a better grasp of the relationship between available COVID vaccines and the Delta variant.
